目的：观察芦可替尼治疗真性红细胞增多症继发骨髓纤维化的临床疗效和不良反

Objective: To observe the reed can imatinib treatment polycythemia vera myelofibrosis secondary clinical efficacy and adverse reactions. Methods: A patient diagnosis in April 2018 Lu'an City, Anhui Province People's Hospital treated as secondary polycythemia vera myelofibrosis patients can be oral Lo imatinib before and after the blood, spleen size, MPN100 score changes and adverse reactions. Results: One patient taking imatinib Lo can follow-up nine months, significantly reduced spleen, not palpable ribs, blood stable, but the lymphatic cases. Conclusion: Lo imatinib may improve bone marrow fibrosis quality of life, improve the clinical symptoms, should pay attention to immunosuppression side effects associated TB recurrence and spread.

Objective: To observe the clinical efficacy and adverse reactions of reseutics to treat secondary bone marrow fibrosis. Methods: In April 2018, 1 patient admitted to the People's Hospital of Sixan City, Anhui Province, was diagnosed with oral rectantiand imoron alfide, changes in spleen size, MPN100 score and adverse reactions in patients with secondary bone marrow fibrosis of true erythkaghyperpheniacasis. Results: 1 patient took reedtinib follow-up for 9 months, the spleen significantly reduced, under the ribs can not be used, blood is generally stable, but the case appeared lymphatic tuberculosis. Conclusion: Reokinib can improve the quality of bone marrow fibrosis quality, so that patients' clinical symptoms improve, should pay attention to immunosuppression-related side effects of tuberculosis recurrence and spread.

Objective: To observe the clinical effect and side effects of lucotinib in the treatment of myelofibrosis secondary to polycythemia vera. Methods: in April 2018, a case of bone marrow fibrosis secondary to polycythemia vera diagnosed by the people's Hospital of Lu'an City in Anhui Province was treated with lucotinib before and after oral administration, including the changes of blood routine, spleen size, mpn100 score and adverse reactions. Results: one patient was followed up for 9 months after taking lucotinib, the spleen was obviously reduced, the subcostal area could not be palpated, the blood routine was stable, but this patient had lymphotuberculosis. Conclusion: lucotinib can improve the quality of life of patients with myelofibrosis and improve their clinical symptoms. We should pay attention to the recurrence and spread of tuberculosis related to immunosuppression.